Fig. 6

Establishment of HCC EV TR Scores for differentiating post-Tx viable and post-Tx nonviable HCC in the training set (n = 49). A Pre-Tx and post-Tx plasma samples from each HCC patient were subjected to the refined HCC EV Digital Scoring Assay to generate the respective pre-Tx and post-Tx HCC EV Digital Scores and calculate ∆ HCC EV Digital Scores by subtracting the post-Tx from pre-Tx Scores. A logistic regression model was developed to synergistically combine the post-Tx HCC EV Digital Scores and ∆ HCC EV Digital Scores to establish their HCC EV TR Scores. B Ladder plots summarizing the pre-Tx and post-Tx HCC EV Digital Scores for the 33 post-Tx viable HCC patients and 16 post-Tx nonviable HCC patients. C/D Boxplots summarizing ∆ HCC EV Digital Scores and HCC EV TR Scores of the 33 post-Tx viable HCC patients and the 16 post-Tx nonviable HCC patients. The dashed line indicates the optimal cutoff of 0.76. E ROC curve of HCC EV TR Score for differentiating post-Tx viable HCC from post-Tx nonviable HCC in the training set. F ROC curve after leave-one-out cross-validation for differentiating post-Tx viable HCC from post-Tx nonviable HCC in the training set. AUROC, area under receiver operating characteristic curve; EV, extracellular vesicle; HCC, hepatocellular carcinoma; LT, liver transplantation; ROC, receiver operating characteristic; RT-dPCR, reverse-transcription digital PCR; TACE, transarterial chemoembolization; TARE, transarterial radioembolization; TR, treatment response; Tx, treatment